CD19 and acute lymphoblastic leukemia: The early success of blinatumomab, a bispecific T cell engager targeting CD19 and CD3 for relapsed/refractory ALL [18], suggests that BsAbs directed against myeloid-specific antigens could similarly transform clinical outcomes in pediatric AML.